Lytix Biopharma AS (DE:6BG) has released an update.
Lytix Biopharma AS, a leading Norwegian immuno-oncology company, is set to present its Q3 2024 financial results on November 19 through a live webcast featuring CEO Øystein Rekdal and CFO Gjest Breistein. The event will provide key insights into the company’s performance and strategic direction. Investors and interested parties can register for the event and participate in a Q&A session.
For further insights into DE:6BG stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Alphabet’s Waymo Expands Robotaxi Rides in Los Angeles to All Passengers
- Pfizer Considers Selling Hospital Unit to Free Up Cash and Reduce Debt
- Trump’s Win Is Good News for Alphabet Stock, Says Top Investor
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
